ASP015K

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Patients With Impaired Hepatic Function

Conditions

Patients With Impaired Hepatic Function

Trial Timeline

Dec 28, 2015 → Sep 27, 2016

NCT ID

NCT02586194

About ASP015K

ASP015K is a phase 1 stage product being developed by Astellas Pharma for Patients With Impaired Hepatic Function. The current trial status is completed. This product is registered under clinical trial identifier NCT02586194. Target conditions include Patients With Impaired Hepatic Function.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02586194	Phase 1	Completed	Dec 28, 2015	Sep 27, 2016	Patients With Impaired Hepatic Function
NCT02603497	Phase 1	Completed	Nov 24, 2015	Dec 19, 2016	Patients With Impaired Renal Function
NCT01929577	Phase 1	Completed	May 1, 2013	Aug 1, 2013	Bioavailability of ASP015K
NCT01484964	Phase 1	Completed	Sep 1, 2011	Oct 1, 2011	Pharmacokinetics of ASP015K
NCT01486017	Phase 1	Completed	Sep 1, 2011	Sep 1, 2011	Bioavailability of ASP015K
NCT01406132	Phase 1	Completed	Dec 1, 2009	Jan 1, 2010	Healthy Subjects

Competing Products

20 competing products in Patients With Impaired Hepatic Function

See all competitors

Product	Company	Stage	Hype Score
R744 + R744	Chugai Pharmaceutical	Phase 3	77
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo	Chugai Pharmaceutical	Phase 3	77
R744 + Epoetin beta	Chugai Pharmaceutical	Phase 3	77
R744 + R744	Chugai Pharmaceutical	Phase 3	77
R744 + R744	Chugai Pharmaceutical	Phase 3	77
R744	Chugai Pharmaceutical	Phase 3	77
PLX3397 + Temozolomide	Daiichi Sankyo	Phase 1/2	41
FK949E	Astellas Pharma	Phase 1	33
roxadustat	Astellas Pharma	Phase 3	77
roxadustat	Astellas Pharma	Phase 3	77
Roxadustat + Darbepoetin alfa	Astellas Pharma	Phase 3	77
ASP8825	Astellas Pharma	Phase 1	33
ASP015K	Astellas Pharma	Phase 1	33
ASP7991	Astellas Pharma	Phase 1	33
Roxadustat + Epoetin Alfa	Astellas Pharma	Phase 3	77
ATG-F	Astellas Pharma	Approved	85
Celecoxib	Astellas Pharma	Pre-clinical	23
roxadustat + Darbepoetin alfa	Astellas Pharma	Phase 3	77
roxadustat	Astellas Pharma	Phase 3	77
FK949E	Astellas Pharma	Phase 1	33

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved